![]() ![]() Likewise, the Series A investor representative, William Burkoth, notified the board on Maof his intent to not stand for reelection at the company’s 2021 annual meeting of stockholders. As a result of becoming a publicly-traded company, the Series B investor representative, Tony Yao, M.D., Ph.D., notified the board of his intent to resign, effective March 20, 2021. Strengthened corporate governance with appointments to its board of directors including John Milligan Ph.D., as Executive Chairman, and Susannah Gray, Nancy Miller-Rich and Shawn Tomasello as independent members.Together with the completion of a Series C financing earlier in the year, the company raised approximately $298 million in gross proceeds in 2020. Completed upsized initial public offering in December 2020 which raised $222 million in gross proceeds, including the full exercise of the underwriters option to purchase additional shares.4D-710 is a product candidate for cystic fibrosis lung disease which is designed for efficient single dose aerosol delivery in a broad range of patients. Initiated 4D-710 IND-enabling studies and submitted preclinical dataset for presentation at upcoming medical meeting.4D-150 is a wholly owned product candidate for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) and is engineered for three distinct mechanisms-of-action. Initiated IND-enabling studies for 4D-150, an intravitreal R100 vector-based product candidate, and submitted preclinical dataset for presentation at upcoming medical meeting.The primary endpoints of this trial are to evaluate safety and to define the maximum-tolerated/-feasible dose. To date, 4D-110 has been well-tolerated and has not resulted in dose-limiting toxicity or serious adverse events. The dose expansion portion of the trial will enroll patients at the highest dose tested of 1E12 vg/eye. Dose escalation was completed following the dosing of six patients in two cohorts. Completed the dose escalation portion of the Phase 1/2 clinical trial of 4D-110, an intravitreal R100 vector-based product candidate, in adult patients with choroideremia.To date, 4D-125 has been well-tolerated and has not resulted in dose-limiting toxicity or serious adverse events. Completed the dose escalation portion of the Phase 1/2 clinical trial of 4D-125, an intravitreal R100 vector-based product candidate, in adult patients with X-linked retinitis pigmentosa (XLRP).The Phase 1/2 open-label, dose-escalation and dose-expansion clinical trial is expected to enroll up to 18 Fabry disease patients. Dosed the first patient in the Phase 1/2 clinical trial of 4D-310 for the treatment of Fabry disease in March 2021.With the proceeds from our IPO, we raised the capital necessary to expand our vision for developing transformative next-generation gene therapies in multiple therapeutic areas for both rare and large market diseases.” In addition, we strengthened our leadership team and corporate governance, with the addition of key clinical development executives and four experienced board members, including our Executive Chairman John Milligan, Ph.D. “We transitioned into a clinical-stage company, with three product candidates currently in clinical development: 4D-125 for X-linked retinitis pigmentosa, 4D-110 for choroideremia, and 4D-310 for Fabry disease. “2020 was a transformational year for 4D Molecular Therapeutics,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. Cash and cash equivalents of approximately $277M as of Dec 31, 2020ĮMERYVILLE, Calif., Ma(GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the year ended Decemand provided operational highlights. Intravitreal product candidate 4D-150 for the treatment of wet AMD and DME on track to initiate clinical trial in the second half of 2021 Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment of choroideremia, completed dose escalation portion of Phase 1/2 clinical trials (n=12 patients) First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |